• Mashup Score: 0
    Breast Cancer Treatment: How is Biology's Integration into the Clinic Transforming Healthcare? Hope Rugo - 2 year(s) ago

    Breast Cancer Treatment: How is Biology’s Integration into the Clinic Transforming Healthcare? Hope Rugo By Hope Rugo, MD, FASCO, Professor, Medicine at Professor, Department of Medicine (Hematology/Oncology); Director, Breast Oncology and Clinical Trials Education; and Medical Director of Cancer Infusion Services, …

    Source: oncologytube.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      🎗️ Exciting read on #BreastCancer treatment! Discover how the integration of biology into clinical practice is revolutionizing healthcare. Dr. Hope Rugo sheds light on transformative advancements. Watch Here: https://t.co/vlT5ICvXIc @hoperugo @UCSFCancer #BreastCancerTreatment https://t.co/Qqidv2JVPM

  • Mashup Score: 3
    Emergency department visits and hospitalizations in older women treated for early stage breast cancer - 2 year(s) ago

    Older patients with cancer often require acute care treatment through emergency department (ED) visits and hospitalizations. This study investigates acute care utilization through ED visits and hospitalizations during treatment and in the two years following the completion of primary treatment for early stage breast cancer (EBC) in women aged 65 and older.

    Source: Journal of Geriatric Oncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JGeriOnc
      JGeriOnc

      Emergency department visits and hospitalizations in older women treated for early stage breast cancer https://t.co/6Z1cU4Oi6t @DrHymanMuss @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #BreastCancerTreatment #AcuteCareUtilization https://t.co/63VRa0LMoF

  • Mashup Score: 2
    ASCO Releases Rapid Guideline Recommendation Update for Certain Patients With Hereditary Breast Cancer - 4 year(s) ago

    A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. The recommendations update the 2020 guideline from ASCO, the American Society for Radiation…

    Source: ASCO
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TJH0828
      TJH0828

      A new @ASCO @ASCOPost guideline update recommends offering 1 year of adjuvant olaparib to high-risk early-stage BRCA+ #breastcancer patients ... https://t.co/1rn1x0G64c #bcsm #PrecisionMedicine #breastcancertreatment